Clinically relevant mitochondrial-targeted therapy improves chronic outcomes after traumatic brain injury

Pioglitazone, an FDA-approved compound, has been shown to target the novel mitochondrial protein mitoNEET and produce short-term neuroprotection and functional benefits following traumatic brain injury. To expand on these findings, we now investigate the dose- and time-dependent effects of pioglitaz...

Descripción completa

Detalles Bibliográficos
Autores principales: Hubbard, W Brad, Spry, Malinda L, Gooch, Jennifer L, Cloud, Amber L, Vekaria, Hemendra J, Burden, Shawn, Powell, David K, Berkowitz, Bruce A, Geldenhuys, Werner J, Harris, Neil G, Sullivan, Patrick G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719838/
https://www.ncbi.nlm.nih.gov/pubmed/34972207
http://dx.doi.org/10.1093/brain/awab341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719838/
https://www.ncbi.nlm.nih.gov/pubmed/34972207
http://dx.doi.org/10.1093/brain/awab341

Ejemplares similares